SI2389382T1 - Amino-heterociklične spojine, uporabljene kot inhibitorji pde9 - Google Patents
Amino-heterociklične spojine, uporabljene kot inhibitorji pde9Info
- Publication number
- SI2389382T1 SI2389382T1 SI201030250T SI201030250T SI2389382T1 SI 2389382 T1 SI2389382 T1 SI 2389382T1 SI 201030250 T SI201030250 T SI 201030250T SI 201030250 T SI201030250 T SI 201030250T SI 2389382 T1 SI2389382 T1 SI 2389382T1
- Authority
- SI
- Slovenia
- Prior art keywords
- amino
- compounds used
- heterocyclic compounds
- pde9 inhibitors
- pde9
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20609209P | 2009-01-26 | 2009-01-26 | |
PCT/IB2010/050133 WO2010084438A1 (en) | 2009-01-26 | 2010-01-13 | Amino-heterocyclic compounds used as pde9 inhibitors |
EP10701921.8A EP2389382B1 (en) | 2009-01-26 | 2010-01-13 | Amino-heterocyclic compounds used as pde9 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2389382T1 true SI2389382T1 (sl) | 2013-07-31 |
Family
ID=42062324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201030250T SI2389382T1 (sl) | 2009-01-26 | 2010-01-13 | Amino-heterociklične spojine, uporabljene kot inhibitorji pde9 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8278295B2 (sl) |
EP (1) | EP2389382B1 (sl) |
JP (1) | JP5656874B2 (sl) |
KR (1) | KR101417237B1 (sl) |
CN (1) | CN102292340B (sl) |
AR (1) | AR074966A1 (sl) |
AU (1) | AU2010207507B2 (sl) |
CA (1) | CA2748864C (sl) |
DK (1) | DK2389382T3 (sl) |
ES (1) | ES2420860T3 (sl) |
HK (1) | HK1163092A1 (sl) |
HR (1) | HRP20130530T1 (sl) |
IL (2) | IL213923A (sl) |
MX (1) | MX2011007862A (sl) |
PL (1) | PL2389382T3 (sl) |
PT (1) | PT2389382E (sl) |
SG (1) | SG172805A1 (sl) |
SI (1) | SI2389382T1 (sl) |
TW (1) | TWI404721B (sl) |
UY (1) | UY32391A (sl) |
WO (1) | WO2010084438A1 (sl) |
ZA (1) | ZA201105931B (sl) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
BRPI0922057A2 (pt) | 2008-11-19 | 2015-12-15 | Envivo Pharmaceuticals Inc | tratamento dos transtorno cognitivos com (r)-7-cloro-n-(quiniclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmeceuticamente aceitaveis do mesmo |
JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα7ニコチン酸受容体を用いた認知障害の治療 |
RS56812B1 (sr) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-hloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidrohlorid monohidrata |
JP5888237B2 (ja) | 2010-09-07 | 2016-03-16 | アステラス製薬株式会社 | ピラゾロキノリン化合物 |
JP5822080B2 (ja) | 2010-09-07 | 2015-11-24 | アステラス製薬株式会社 | キノキサリン化合物 |
EP3121178B1 (en) | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
WO2013110768A1 (en) | 2012-01-26 | 2013-08-01 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗-TNFα療法無效之克隆氏症患者之用途 |
WO2013169646A1 (en) | 2012-05-08 | 2013-11-14 | Envivo Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
CN102786525B (zh) * | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
CN103207246B (zh) * | 2012-12-21 | 2017-10-10 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法 |
EP3139924A4 (en) * | 2014-05-06 | 2018-03-07 | Anthony G. Visco | Methods of treating or preventing preterm labor |
EP3186224B1 (en) * | 2014-08-27 | 2021-04-21 | F. Hoffmann-La Roche AG | Substituted azetidine derivatives as taar ligands |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
CN107810187B (zh) | 2015-07-07 | 2020-09-15 | H.隆德贝克有限公司 | 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂 |
US10370337B2 (en) | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
WO2017019724A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
WO2017019723A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Aza-cyanoquinolinone pde9 inhibitors |
WO2017048720A1 (en) | 2015-09-15 | 2017-03-23 | Praxis Biosciences, Llc | Prodrugs of fencamfamine |
CN105467028A (zh) * | 2015-11-18 | 2016-04-06 | 北京万全德众医药生物技术有限公司 | 气相色谱法分离测定鲁拉西酮中间体光学异构体的方法 |
CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
EP3481398A1 (en) | 2016-07-06 | 2019-05-15 | Imara, Inc. | Pde9 inhibitors for treatment of peripheral diseases |
ES2967489T3 (es) * | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
CA3041607A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
WO2018091687A1 (en) | 2016-11-18 | 2018-05-24 | Integrative Research Laboratories Sweden Ab | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Pde2阻害剤としての置換ピラゾロピリミジノン化合物 |
KR102643197B1 (ko) * | 2017-02-23 | 2024-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 화합물 iii의 새로운 의학 용도 |
CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基)吡啶二盐酸盐的合成方法 |
MX2019013626A (es) * | 2017-05-22 | 2020-01-13 | Topadur Pharma Ag | Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos. |
HRP20240146T1 (hr) * | 2017-05-26 | 2024-04-12 | Cardurion Pharmaceuticals, Inc. | Postupci dobivanja i upotrebe inhibitora pde9 |
WO2018221550A1 (ja) * | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
US11484502B2 (en) | 2017-06-01 | 2022-11-01 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
IL270395B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | A therapeutic agent for dementia that combines a pyrozoloquinoline derivative and donepezil |
TW201902898A (zh) | 2017-06-08 | 2019-01-16 | 美商默沙東藥廠 | 吡唑并嘧啶pde9抑制劑 |
KR20200108419A (ko) | 2017-11-27 | 2020-09-18 | 다트 뉴로사이언스, 엘엘씨 | Pde1 억제제로서의 치환된 푸라노피리미딘 화합물 |
SG11202109781QA (en) * | 2019-03-08 | 2021-10-28 | Transthera Sciences Nanjing Inc | Uses of phosphodiesterase inhibitors |
CN114450005A (zh) * | 2019-07-29 | 2022-05-06 | 星座制药公司 | 用于治疗神经障碍的化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法 |
GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
SE0103795D0 (sv) | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Compounds and method for the treatment of överactive bladder |
US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
JP4464136B2 (ja) * | 2001-12-06 | 2010-05-19 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害薬 |
GEP20125405B (en) * | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
-
2009
- 2009-12-31 TW TW098146481A patent/TWI404721B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 CN CN201080005394.XA patent/CN102292340B/zh not_active Expired - Fee Related
- 2010-01-13 SI SI201030250T patent/SI2389382T1/sl unknown
- 2010-01-13 EP EP10701921.8A patent/EP2389382B1/en not_active Not-in-force
- 2010-01-13 PL PL10701921T patent/PL2389382T3/pl unknown
- 2010-01-13 DK DK10701921.8T patent/DK2389382T3/da active
- 2010-01-13 CA CA2748864A patent/CA2748864C/en not_active Expired - Fee Related
- 2010-01-13 SG SG2011047594A patent/SG172805A1/en unknown
- 2010-01-13 KR KR1020117019758A patent/KR101417237B1/ko not_active IP Right Cessation
- 2010-01-13 JP JP2011547011A patent/JP5656874B2/ja not_active Expired - Fee Related
- 2010-01-13 PT PT107019218T patent/PT2389382E/pt unknown
- 2010-01-13 WO PCT/IB2010/050133 patent/WO2010084438A1/en active Application Filing
- 2010-01-13 ES ES10701921T patent/ES2420860T3/es active Active
- 2010-01-13 MX MX2011007862A patent/MX2011007862A/es active IP Right Grant
- 2010-01-13 AU AU2010207507A patent/AU2010207507B2/en not_active Ceased
- 2010-01-25 UY UY0001032391A patent/UY32391A/es not_active Application Discontinuation
- 2010-01-25 AR ARP100100153A patent/AR074966A1/es unknown
- 2010-01-26 US US12/693,480 patent/US8278295B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 IL IL213923A patent/IL213923A/en not_active IP Right Cessation
- 2011-08-12 ZA ZA2011/05931A patent/ZA201105931B/en unknown
-
2012
- 2012-04-18 HK HK12103808.2A patent/HK1163092A1/xx not_active IP Right Cessation
- 2012-08-31 US US13/600,522 patent/US8618117B2/en not_active Expired - Fee Related
-
2013
- 2013-06-12 HR HRP20130530AT patent/HRP20130530T1/hr unknown
- 2013-11-27 US US14/091,404 patent/US20140088081A1/en not_active Abandoned
-
2016
- 2016-07-21 IL IL246882A patent/IL246882A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL246882A0 (en) | Amino-heterocyclic compounds used as pde9 inhibitors | |
HUS2000024I1 (hu) | Béta laktamáz inhibitorok | |
HK1223565A1 (zh) | 粘土組合物 | |
IL216145A0 (en) | Dihydropyrimidinones for use as bace2 inhibitors | |
EP2584903A4 (en) | NEW HETEROCYCLIC COMPOUNDS AS ERK HEMMER | |
IL225770A0 (en) | Heterocyclic compounds | |
EP2483263A4 (en) | NOVEL ERK INHIBITORY COMPOUNDS | |
HK1155172A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
GB201016880D0 (en) | Phosphodiesterase inhibitors | |
ZA201100898B (en) | Novel inhibitors | |
EP2434885A4 (en) | ALKOXY TETRA HYDRO-pyridopyrimidine PDE10 INHIBITORS | |
EP2629616A4 (en) | SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER | |
EP2632268A4 (en) | NEW CONNECTIONS AS ERK HEMMER | |
EP2563379A4 (en) | SOX9 INHIBITORS | |
EP2559508A4 (en) | DRILLING DEVICE | |
ZA201102837B (en) | Phosphodiestarase inhibitors | |
GB2485540B (en) | Brick | |
EP2659998A4 (en) | DRILL | |
GB0804242D0 (en) | Clopidogrel solution | |
GB0902661D0 (en) | Inhibitors | |
GB0903650D0 (en) | Glyoalase inhibitors | |
GB0915927D0 (en) | Novel inhibitors | |
GB201018597D0 (en) | Inhibitors | |
GB0816125D0 (en) | Novel inhibitors | |
GB201006605D0 (en) | Novel inhibitors |